### Unseen Epidemic: Millions Unaware of Severe Fatty Liver Disease

A startling 17 million people across the United States, United Kingdom, Germany, and France are unknowingly living with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of fatty liver disease. This discovery, highlighted in a new study, points to an alarming health concern. MASH, a progression of metabolic dysfunction-associated steatotic liver disease (MASLD), predominantly affects those who consume little to no alcohol and has strong links to type 2 diabetes, obesity, and cardiovascular conditions.

The study, published in the Lancet Regional Health Europe, estimates that around 5% of the global adult population and 4% of Americans have MASH. The disease leads to liver scarring and elevates the risk of severe health issues such as cirrhosis, kidney disease, and liver cancer. Alarmingly, fewer than 20% of individuals with MASH are diagnosed, meaning the vast majority remain oblivious to their condition.

Researchers urge a significant increase in diagnosis rates from 2022 levels to prevent a surge in medical costs and individual suffering. Non-invasive methods such as blood tests and MRI scans are recommended, especially for those with type 2 diabetes, obesity with additional risk factors, and persistently high liver enzymes.

Experts warn that without improved identification and treatment, the health and economic ramifications will expand. They advocate for increased utilization of weight-loss drugs like Wegovy and Mounjaro, which can help reduce calorie intake, promote weight loss, and potentially lessen liver scarring. Additionally, the diabetes medication dapagliflozin shows promise in reducing liver fat and fibrosis, hinting at the evolving role of pharmaceuticals in managing this growing health issue.